Inovio Adds Its Strategic Adviser To The Board, Expanding From Eight Directors To Nine
Jeffrey Libson also joined the Finance Committee, with annual cash retainers and future equity awards under the director pay program.
Inovio Pharmaceuticals, which develops DNA medicines for HPV-related diseases, cancer and infectious diseases, appointed Jeffrey Libson on Friday and expanded its board to nine directors from eight. The company reported the appointment in an SEC filing Tuesday after markets closed; Libson has been its mentor and strategic adviser since January 2025.
A Finance Committee Seat And Retainers
Libson joined the Finance Committee on Friday as well. His annual cash pay includes $45,000 for board service and another $5,000 for committee work, with payments prorated under Inovio's pay program for directors who are not employees.
Inovio also plans to give him future equity awards through that program. His initial board term extends to the company's 2027 annual shareholder meeting and the election and qualification of a successor, unless he leaves earlier.
From Life Sciences Counsel To Director
Libson, 72, advised life sciences businesses, their boards, entrepreneurs and investors as a partner at Cooley. He worked there from December 2016 to January 2025 and belonged to its Global Life Sciences Leadership Team.
His legal career also included Pepper Hamilton, where he worked from August 1981 to December 2016 and led the life sciences practice. He taught graduate students about life sciences entrepreneurship as an adjunct professor at the University of Pennsylvania's Wharton School from September 2006 to January 2025.
Libson has served on the Sabin Vaccine Institute's board of trustees since May 2020 and Eastern University's since February 2026. He earned an economics and English bachelor's degree at Oberlin College and a law degree at Duke University School of Law.
DNA Medicines Still In Development
Inovio's lead candidate, INO-3107, targets recurrent respiratory papillomatosis, a rare illness that produces airway tumors. Its other candidates include treatments aimed at throat cancer and other cancers.
The company's medicines use small circular DNA molecules called plasmids to instruct cells to produce specific proteins. Its CELLECTRA devices use short electrical pulses to deliver the medicines into cells.
Inovio's annual report for the fiscal year ended December 31, 2025, described all its candidates as still in research and development. The company has earned revenue through licensing fees, milestone payments and collaborative research agreements and contracts, but has not generated product-sales revenue.
Sources
- 8-K Filing — INOVIO PHARMACEUTICALS, INC. (INO) — SEC EDGAR